Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering

• Published in: Critical reviews in biotechnology Vol. 43; no. 3; pp. 484 - 502
• Main Authors: Beauglehole, Aiden C., Roche Recinos, Dinora, Pegg, Cassandra L., Lee, Yih Yean, Turnbull, Victor, Herrmann, Susann, Marcellin, Esteban, Howard, Christopher B., Schulz, Benjamin L.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.04.2023
• Subjects: Animals; bioprocessing; Cell Engineering; Chinese hamster ovary cell; CHO Cells; Cricetinae; Cricetulus; Factor IX - metabolism; factor IX production; Humans; post-translational modifications; Quality of Life; recombinant factor IX; Recombinant Proteins - metabolism; bioprocessing; recombinant factor IX; cell engineering; Chinese hamster ovary cell; post-translational modifications; factor IX production
• ISSN: 0738-8551; 1549-7801
• DOI: 10.1080/07388551.2022.2036691

Appropriate treatment of Hemophilia B is vital for patients' quality of life. Historically, the treatment used was the administration of coagulation Factor IX derived from human plasma. Advancements in recombinant technologies allowed Factor IX to be produced recombinantly. Successful recombinant production has triggered a gradual shift from the plasma derived origins of Factor IX, as it provides extended half-life and expanded production capacity. However, the complex post-translational modifications of Factor IX have made recombinant production at scale difficult. Considerable research has therefore been invested into understanding and optimizing the recombinant production of Factor IX. Here, we review the evolution of recombinant Factor IX production, focusing on recent developments in bioprocessing and cell engineering to control its post-translational modifications in its expression from Chinese Hamster Ovary (CHO) cells.